Type of Study: Epidemiological

Sponsor / Support: LACOG, GBOT, Takeda

Primary Objectives: The general objective of this study is to describe the treatment sequencing of ALK-positive advanced NSCLC in a real-world setting.

Design: An observational, retrospective cohort study

Sample Size: 70 to 100 patients

Principal Investigator: Eldsamira Mascarenhas

Countries LATAM: Brazil